The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

This publication has 27 references indexed in Scilit:

• Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day
  European Journal of Cancer and Clinical Oncology, 1985
• Analysis of survival by tumor response.
  Journal of Clinical Oncology, 1983
• Comparison of four-combination chemotherapy programs in metastatic breast cancer. Comparison of multiple drug therapy with cytoxan, 5-fu and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-Fu and adriamycin, versus cytoxan, 5-Fu and prednisone alternating with cytoxan and adriamycin
  Cancer, 1982
• Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen
  Cancer, 1982
• Chemotherapy vs. chemoimmunotherapy with methanol extraction residue of bacillus calmette-guerin (MER) in advanced breast cancer: A randomized trial by the piedmont oncology association
  Cancer, 1981
• Reporting results of cancer treatment
  Cancer, 1981
• Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG
  Cancer, 1979
• Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin
  Cancer, 1979
• Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland
  Cancer, 1977
• An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer
  Cancer, 1975